Format

Send to

Choose Destination
Ann Clin Lab Sci. 2017 Jan;47(1):88-91.

Morphoproteomics Identifies the EZH2 and SIRT1 Pathways as Potential Blocks to Differentiation in Yolk Sac Tumor of the Ovary and Provides Therapeutic Options: a Case Study.

Author information

1
Department of Pathology and Laboratory Medicine, UT Health-McGovern Medical School, Houston, TX, USA Yumi.a.kojima@uth.tmc.edu.
2
Department of Pathology and Laboratory Medicine, UT Health-McGovern Medical School, Houston, TX, USA.
3
Department of Obstetrics and Gynecology UT Health-McGovern Medical School, Houston, TX, USA.

Abstract

Yolk sac tumor of the ovary is a rare but highly malignant and aggressive germ cell tumor. The objective of this case study of an ovarian yolk sac tumor was to identify putative pathways that are known to pose a block in differentiation, both in early embryogenesis and in tumorigenesis, that might be amenable to low toxicity therapies designed to promote differentiation to a more benign state and prevent recurrent disease in such tumors. The enhancer of Zeste homolog 2 (EZH2), a histone methyl transferase, and silent mating type information regulation 2 homolog 1 (SIRT1), a NAD+ histone deacetylase, are two such pathways.

KEYWORDS:

EZH2; Morphoproteomics; SIRT1; yolk sac tumor

PMID:
28249923
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center